Abstract
AbstractThe coronavirus disease 2019 (COVID-19) pandemic has become a worldwide emergency. In the attempt to search for interventions that would improve outcomes, some studies have looked at the potential benefit of BCG vaccination. These past studies have found a statistically significant reduction in COVID-19 related mortality in countries with a current universal bacille Calmette-Guérin (BCG) vaccination policy. However, just as the authors themselves noted, the nature of ecological studies make them very prone to the presence of several confounders. This paper took into account demographic differences, economic differences and the different stages of the pandemic in each country; gathering data from publicly available sources. It was found that no statistically significant difference exists in mortality rates between countries with a current or prior BCG vaccination policy when compared to those that never had such a program. Nevertheless, the immunostimulatory potential of the BCG vaccine might still prove useful in the development of future vaccines or other prophylactic measures.
Publisher
Cold Spring Harbor Laboratory
Reference62 articles.
1. Jason Oke , Carl Heneghan . Global Covid-19 Case Fatality Rates. Centre for Evidence Based Medicine, Published March 17, 2020. Last Updated April 7, 2020. Accessed April 10, 2020. Available at:https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/
2. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines;npj Vaccines,2020
3. Differential COVID-19-attributable mortality and BCG vaccine use in countries
4. Correlation between universal BCG vaccination policy and reduced mortality for COVID-19
5. WITHDRAWN: Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic?
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献